1029691-06-2 Usage
General Description
"1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-" is a chemical compound that belongs to the class of isoindole-1,3-dione derivatives. It is also known as 2-(3-oxocyclopentyl)isoindoline-1,3-dione. 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)- is characterized by a unique cyclic structure containing a cyclopentyl ring and a isoindole-1,3-dione core. It has various potential applications in the field of organic synthesis and medicinal chemistry due to its structural features and functional groups. Additionally, it can be utilized as a building block in the preparation of novel compounds with potential biological activities. Further research and investigation are necessary to fully understand the properties and potential uses of this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 1029691-06-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,9,6,9 and 1 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1029691-06:
(9*1)+(8*0)+(7*2)+(6*9)+(5*6)+(4*9)+(3*1)+(2*0)+(1*6)=152
152 % 10 = 2
So 1029691-06-2 is a valid CAS Registry Number.
1029691-06-2Relevant articles and documents
PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
-
Paragraph 0494, (2021/04/30)
Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Paragraph 0745, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
HEPATITIS B ANTIVIRAL AGENTS
-
Page/Page column 214, (2013/07/05)
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.